Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 11:36 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 4,668 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Nov 2, 2026, 11:36 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Acute Respiratory Infection Consortium

NCT01021098
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
17 Years to 55 Years
Enrollment
2,018 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 1 Interventional

A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP

NCT00000998
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 2, 2026, 11:36 PM EST
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 2, 2026, 11:36 PM EST
Active, not recruiting Phase 2 Interventional

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT03010436
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Nov 2, 2026, 11:36 PM EST
Recruiting Phase 3 Interventional

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

NCT06745908
View directory record Official record
Conditions
NSCLC Stage IV
Interventions
N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
32
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • El Segundo, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

NCT00452400
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Asthma
Interventions
BI 1744CL
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Lakewood, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Nov 2, 2026, 11:36 PM EST
Withdrawn No phase listed Observational

Sexual Dysfunction And Hypotestosteronemia In Patients With Obstructive Sleep Apnea Syndrome

NCT00832065
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Sleep Apnea, Hypotestosteronism
Interventions
Not listed
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 70 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Burlington, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

NCT01156792
View directory record Official record
Conditions
Asthma
Interventions
FP 100, GSK2190915 100, GSK2190915 300, montelukast, placebo, FP/SAL 100/50
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Nov 2, 2026, 11:36 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study of Nicotine Patches in Patients With Sarcoidosis

NCT00701207
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
nicotine patch
Drug
Lead sponsor
Elliott Crouser MD
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Nov 2, 2026, 11:36 PM EST
Recruiting Not applicable Interventional

Characterizing the Impact of Presbyphonia on Social Interaction

NCT06441136
View directory record Official record
Conditions
Presbyphonia
Interventions
PhoRTE Program, University of California Los Angeles (UCLA) Loneliness Scale, Social Disconnectedness Scale, Patient Health Questionnaire 9, Aging Voice Index, The Edmonton Frail Scale, Vocal Effort Scale, Montreal Cognitive Assessment, Voice Handicap Index-10, Voice Problem Impact Scales, Cough Severity Index, Laryngoscopy, Acoustic, perceptual, and aerodynamic assessments
Other · Procedure
Lead sponsor
Matthew R. Hoffman
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Nov 2, 2026, 11:36 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

NCT00662311
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
vorinostat, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Nov 2, 2026, 11:36 PM EST
Active, not recruiting Phase 1 Interventional

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236
View directory record Official record
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions
SC291
Biological
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 2, 2026, 11:36 PM EST
Not listed Not applicable Interventional

Evaluation Montelukast in the Treatment of Status Asthmaticus

NCT01770899
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Corrie Fletcher
Other
Eligibility
2 Years to 14 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Nov 2, 2026, 11:36 PM EST
Terminated Phase 2 Interventional Results available

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer

NCT00545948
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
13
States / cities
West Palm Beach, Florida • Chicago, Illinois • Charlotte, North Carolina + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 2 Interventional Results available

Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

NCT03481114
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PET-based, dose-painted, accelerated chemoradiotherapy, Standard chemoradiotherapy
Combination Product
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 2 Interventional Results available

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

NCT00647426
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sorafenib + Docetaxel/Carboplatin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 4 Interventional Results available

Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation

NCT01705964
View directory record Official record
Conditions
Asthma
Interventions
IM epinephrine 1:1000, No intervention
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
6 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Nov 2, 2026, 11:36 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients

NCT00472264
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PET imaging
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 3 Interventional Results available

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00709098
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
iloprost
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
32
States / cities
La Jolla, California • Sacramento, California • Torrance, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

NCT01072149
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Nov 2, 2026, 11:36 PM EST
Completed Phase 4 Interventional

Nebulized Heparin for the Treatment of COVID-19

NCT04723563
View directory record Official record
Conditions
Covid19, Pneumonia, Viral
Interventions
Heparin, 0.9%sodium chloride
Drug
Lead sponsor
Frederick Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 2, 2026, 11:36 PM EST
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 2, 2026, 11:36 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A New Treatment for Mechanical Nasal Obstruction

NCT03456115
View directory record Official record
Conditions
Nasal Obstruction
Interventions
Mechanical nasal dilator
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 2, 2026, 11:36 PM EST